The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Model-based estimates of tumor growth inhibition (TGI) metrics to predict for overall survival (OS) in first-line non-small cell lung cancer (NSCLC).
Laurent Claret
Employment or Leadership Position - Pharsight
Pierre Mancini
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Bernard Sebastien
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Christine Veyrat-Follet
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Rene Bruno
Employment or Leadership Position - Pharsight